Guan Haixia, Ji Meiju, Hou Peng, Liu Zhi, Wang Cuifang, Shan Zhongyan, Teng Weiping, Xing Mingzhao
Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
Cancer. 2008 Jul 15;113(2):247-55. doi: 10.1002/cncr.23548.
It remains to be investigated whether the aberrant methylation of DNA repair genes plays a pathogenic role in BRAF mutation-promoted tumorigenesis of papillary thyroid cancer (PTC).
In the current study, the promoter methylation status of 23 DNA repair genes in relation to clinicopathologic characteristics and BRAF mutation was examined in PTC tumors using methylation-specific polymerase chain reaction.
Among the 38 PTC tumors examined, 3 of 23 DNA repair genes were hypermethylated, including the hMLH1 gene in 8 of 38 samples (21%), the PCNA gene in 5 of 38 samples (13%), and the OGG1 gene in 2 of 38 samples (5%). Methylation of these genes was also found in some thyroid cancer cell lines. Methylation of the hMLH1 gene in particular was found to be associated with lymph node metastasis of PTC (5 of 8 samples [63%] in the methylation group vs 3 of 30 samples [10%] in the nonmethylation group; P = .0049). Methylation of the hMLH1 gene was also found to be associated with the T1799A BRAF mutation in PTC (6 of 19 samples (32%) in the BRAF mutation-positive group vs 2 of 19 samples (11%) in the BRAF mutation-negative group; P = .042).
The data from the current study suggest that, as shown previously in colon cancer, aberrant methylation of the hMLH1 gene may play a role in BRAF mutation-promoted thyroid tumorigenesis.
DNA修复基因的异常甲基化是否在BRAF突变促进的甲状腺乳头状癌(PTC)肿瘤发生中起致病作用仍有待研究。
在本研究中,使用甲基化特异性聚合酶链反应检测了PTC肿瘤中23个DNA修复基因的启动子甲基化状态及其与临床病理特征和BRAF突变的关系。
在检测的38例PTC肿瘤中,23个DNA修复基因中有3个发生了高甲基化,包括38个样本中的8个(21%)的hMLH1基因、38个样本中的5个(13%)的PCNA基因和38个样本中的2个(5%)的OGG1基因。在一些甲状腺癌细胞系中也发现了这些基因的甲基化。特别是hMLH1基因的甲基化与PTC的淋巴结转移相关(甲基化组8个样本中的5个[63%],非甲基化组30个样本中的3个[10%];P = 0.0049)。还发现hMLH1基因的甲基化与PTC中的T1799A BRAF突变相关(BRAF突变阳性组19个样本中的6个[32%],BRAF突变阴性组19个样本中的2个[11%];P = 0.042)。
本研究数据表明,如先前在结肠癌中所示,hMLH1基因的异常甲基化可能在BRAF突变促进的甲状腺肿瘤发生中起作用。